David Pellegrin, MD
Gastroenterology · Houma, LANPI 1679662936
Payments from drug & device makers
Across 232 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$926
- Takeda Pharmaceuticals U.S.A., Inc.$417
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$139
- Madrigal Pharmaceuticals$105
- Phathom Pharmaceuticals, Inc.$102
- plus $520 from 14 others
What the payments were for
- Food & beverage$3,95699%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 103 | $1,770 |
| Johnson & Johnson(2 entities) | 58 | $926 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $417 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $139 |
| Madrigal Pharmaceuticals | 5 | $105 |
| Phathom Pharmaceuticals, Inc. | 6 | $102 |
| Bristol Myers Squibb | 6 | $98 |
| Nestle Healthcare Nutrition Inc. | 3 | $67 |
| Sanofi | 4 | $58 |
| Merck | 3 | $46 |
| Ferring Pharmaceuticals Inc. | 3 | $44 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Redhill Biopharma Inc. | 2 | $30 |
| Mauna Kea Technologies, Inc. | 1 | $30 |
| Novo Nordisk | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Fresenius Kabi USA, LLC | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $18 |
| Celltrion USA Inc. | 1 | $16 |
| Capsovision, Inc. | 1 | $14 |
How this compares
$3,981 in reported general payments places this provider in the 50th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 62 | $1,716,830 |
| Humira(Cf) PenAdalimumab | 20 | $155,560 |
| LinzessLinaclotide | 111 | $77,348 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 258 | $44,712 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 244 | $40,300 |
| Mesalamine | 49 | $26,642 |
| Pantoprazole Sodium | 943 | $12,791 |
| CreonLipase/Protease/Amylase | 11 | $11,171 |
| Budesonide EcBudesonide | 47 | $10,728 |
| MovantikNaloxegol Oxalate | 25 | $9,780 |
| Mesalamine ErMesalamine | 16 | $9,230 |
| Colesevelam Hcl | 107 | $7,939 |
| Dicyclomine Hcl | 404 | $7,777 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 113 | $7,569 |
| Omeprazole | 511 | $7,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $926 | $1,716,83062 claims |
| AbbVieLinzess, Creon | $1,770 | $88,519122 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $44 | $44,712258 claims |
| Braintree Laboratories, Inc.Sutab | $18 | $40,300244 claims |
| Redhill Biopharma Inc.Movantik | $30 | $9,78025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Houma
- Humberto AguilarShreveport$13.1M
- Gary ReissMarrero$10M
- Bal BhandariBastrop$6.4M
- Gregory GaspardBaton Rouge$4M
- Jonathon ChapmanBaton Rouge$3.6M
- David DulitzLuling$1.9M
- Conar FittonKenner$1.6M
- Vivek HuilgolNew Orleans$1.6M
- Georges CatinisMetairie$1.3M
- Sarah GloverNew Orleans$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.